<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03536663</url>
  </required_header>
  <id_info>
    <org_study_id>Endexo-001</org_study_id>
    <nct_id>NCT03536663</nct_id>
  </id_info>
  <brief_title>Clinical Study to Assess the Performance of the Dialyzer With Endexo™</brief_title>
  <official_title>An Open-Label Clinical Study to Assess the Performance of the Dialyzer With Endexo™ in End-Stage Renal Disease Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Medical Care North America</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fresenius Medical Care North America</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endexo™ is an additive that is blended into the fiber solution during manufacturing of the&#xD;
      hemodialyzer hollow fibers. The intended purpose of the additive is to increase blood&#xD;
      compatibility in the finished dialyzer, which is referred to as the &quot;dialyzer with Endexo.&quot;&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, sequential, multi-center, open-label study with subjects on&#xD;
      thrice-weekly (in-center) hemodialysis (HD). After a Screening Period, there will be 12&#xD;
      hemodialysis treatments on the Optiflux dialyzer (Optiflux Period), followed by 38 HD&#xD;
      treatments on the dialyzer with Endexo (Endexo Period), and then a Follow-up Visit. The study&#xD;
      population will consist of End-Stage Renal Disease ESRD subjects who are a minimum of 22&#xD;
      years of age. The primary objective of the study is to collect data on the performance of the&#xD;
      dialyzer with Endexo when used to perform hemodialysis (HD) in End-Stage Renal Disease (ESRD)&#xD;
      subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 29, 2018</start_date>
  <completion_date type="Actual">June 17, 2019</completion_date>
  <primary_completion_date type="Actual">April 17, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>12 HD treatments (4 weeks) with Optiflux dialyzer followed by 38 HD treatments (13 weeks) with Endexo dialyzer</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Performance of the Dialyzer With Endexo by Measuring Its in Vivo Ultrafiltration Coefficient</measure>
    <time_frame>15 minutes after the recorded start of hemodialysis with Endexo upon its first use in the study</time_frame>
    <description>Ultrafiltration coefficient (Kuf) is the ratio of ultrafiltration rate in ml/hr to the Transmembrane pressure in mmHg. Both the Ultrafiltration rate and the transmembrane pressure readings are collected from the machine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of Any Adverse Events</measure>
    <time_frame>Optiflux: from enrollment, weeks 1 to 4 (visits 1 to 12); Endexo: from weeks 5 to 17, and follow-up, a total of 17 weeks intervention.</time_frame>
    <description>All adverse events were captured from subject enrollment to the completion of Optiflux period, and to the end of study or withdraws from the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Any Device-related Adverse Events</measure>
    <time_frame>Optiflux: from enrollment, weeks 1 to 4 (visits 1 to 12); Endexo: from weeks 5 to 17, and follow-up, a total of 17 weeks intervention.</time_frame>
    <description>Any device-related adverse events were captured from subject enrollment to the completion of Optiflux period, and to the end of study or withdraws from the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Removal of Urea</measure>
    <time_frame>At visits 1/week 1, 10/week 4, 13/week 5, 22/week 8, 34/week 12, and 46/week 16</time_frame>
    <description>URR = (pre-HD urea - post-HD urea)/pre-HD urea * 100&#xD;
Data across visits were averaged for each subject, and then a group mean and sd were calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Removal of Albumin</measure>
    <time_frame>Pre- and Post- HD at Visits 1/week 1, 13/week 5</time_frame>
    <description>%change = (post-HD - pre-HD)/pre-HD * 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Removal of Beta-2-microglobulin</measure>
    <time_frame>Pre- and Post- HD at Visits 1/week 1, 13/week 5</time_frame>
    <description>% reduction = (post-HD - pre-HD)/pre-HD * 100 with post-HD B2M adjusted to pre- and post HD weights</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Dialyzer Hemocompatibility</measure>
    <time_frame>Assessed at the first time the dialyzers are used in the study , collected pre hemodialysis and 30 minutes after the recorded start of hemodialysis</time_frame>
    <description>The dialyzer hemo-compatibility is measured by measuring the activation of the complement system (C3a, C5a, SC5b-9)</description>
  </other_outcome>
  <other_outcome>
    <measure>Clotting of the Dialyzer</measure>
    <time_frame>visual evaluation of the dialyzer arterial cap will be performed at the end of every hemodialysis treatment to determine the Grade:1,2,3 or 4. (1:no clotting to 4: total clotting), throughout a total of 17 weeks intervention.</time_frame>
    <description>Thrombus scoring will be assessed according to a clotting scale (The graded scoring method)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <arm_group>
    <arm_group_label>Optiflux/Endexo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Optiflux (Active Comparator); Hemodialysis treatments on the Optiflux dialyzer (Optiflux Period) for 4 weeks - Visit 1 to 12 Endexo (Experimental); Subjects continue on Dialyzer with Endexo (Endexo Period) for 13 weeks - Visit 13 to visit 50</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optiflux and Dialyzer with Endexo</intervention_name>
    <description>Hemodialysis (HD) on Optiflux dialyzer from Visit 1 to 12 and followed by HD on the dialyzer with Endexo at visit 13 and continues until visit 50. Dialysis is performed 3 times per week which means the total of the intervention will be 17 weeks.</description>
    <arm_group_label>Optiflux/Endexo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must be an adult, older than 22 years of age.&#xD;
&#xD;
          2. Has been prescribed in-center thrice-weekly HD continuously for at least 180 days&#xD;
             prior to the date of signed informed consent&#xD;
&#xD;
          3. Has been prescribed the Optiflux F160NR dialyzer continuously for at least 30 days&#xD;
             prior to the date of signed informed consent&#xD;
&#xD;
          4. Has a prescribed HD treatment time ≥180 minutes (3 hours) and ≤270 minutes (4.5 hours)&#xD;
&#xD;
          5. Has been on heparin anticoagulation for dialysis and has had no change in heparin&#xD;
             prescription within 14 days prior to the date of signed informed consent&#xD;
&#xD;
          6. Has a most recent single pool Kt/V (spKt/V) ≥1.2 within 45 days prior to the date of a&#xD;
             signed informed consent&#xD;
&#xD;
          7. Has a most recent hemoglobin ≥9 g/dL within 45 days prior to the date of a signed&#xD;
             informed consent&#xD;
&#xD;
          8. Has a most recent platelet count ≥100,000/mm3 within 45 days prior to the date of a&#xD;
             signed informed consent&#xD;
&#xD;
          9. A female of childbearing potential must have a negative serum pregnancy test at the&#xD;
             time of screening and agree to use an acceptable method of contraception during the&#xD;
             study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of citric acid concentrate (such as Citrasate®) at the time of signed informed&#xD;
             consent&#xD;
&#xD;
          2. Known allergic reactions to Endexo&#xD;
&#xD;
          3. Hospitalization within 30 days prior to the date of signed informed consent&#xD;
&#xD;
          4. Presence of active malignancy, congestive heart failure New York Heart Association&#xD;
             (NYHA) Class III or IV, or liver cirrhosis&#xD;
&#xD;
          5. Are receiving or have received chemotherapy / radiation therapy / plasmapheresis&#xD;
             therapy within 90 days prior to the date of signed informed consent&#xD;
&#xD;
          6. Are receiving antibiotics or have used antibiotics within 14 days prior to the date of&#xD;
             signed informed consent&#xD;
&#xD;
          7. Are currently enrolled in or have completed any other investigational product study&#xD;
             within 30 days prior to the date of signed informed consent&#xD;
&#xD;
          8. Has a life expectancy of less than 1 year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shakil Aslam, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fresenius Medical Care RTG, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dylan Steer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>California Institute of Renal Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lisa Weber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Management Inc/ Kansas Nephrology Research Institute, LLC-J/V</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jill Meyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Balboa Nephrology Med Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Balboa Nephrology Med Group</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>92154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Institute of Renal Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Management Inc/ Kansas Nephrology Research Institute, LLC-J/V</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 6, 2018</study_first_submitted>
  <study_first_submitted_qc>May 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2018</study_first_posted>
  <results_first_submitted>August 17, 2020</results_first_submitted>
  <results_first_submitted_qc>October 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 12, 2020</results_first_posted>
  <last_update_submitted>November 13, 2020</last_update_submitted>
  <last_update_submitted_qc>November 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 5, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT03536663/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT03536663/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Hemodialysis patients were recruited at three clinical sites in the USA. 23 subjects were enrolled to this study. The first subject first visit was on August 29, 2018 and the last subject last visit was on April 17, 2019.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Optiflux/Endexo</title>
          <description>Hemodialysis treatments on the dialyzer with Endexo starts at visit 13 and continues until visit 50. Dialysis is performed 3 times per week which means the total of the intervention is approximately 12 weeks.&#xD;
Dialyzer with Endexo: Hemodialysis treatments on the dialyzer with Endexo starts at visit 13 and continues until visit 50. Dialysis is performed 3 times per week which means the total of the intervention is approximately 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Optiflux</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Endexo</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18">One subject completed the Optiflux period but missed Visit 13 and was withdrawn per protocol.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects who sign the ICF, are eligible, are enrolled in the study, and have at least one HD treatment with the dialyzer with Endexo.</population>
      <group_list>
        <group group_id="B1">
          <title>Endexo</title>
          <description>Hemodialysis treatments on the dialyzer with Endexo starts at visit 13 and continues until visit 50. Dialysis is performed 3 times per week which means the total of the intervention is approximately 13 weeks.&#xD;
Dialyzer with Endexo: Hemodialysis treatments on the dialyzer with Endexo starts at visit 13 and continues until visit 50. Dialysis is performed 3 times per week which means the total of the intervention is approximately 13 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.28" spread="14.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Performance of the Dialyzer With Endexo by Measuring Its in Vivo Ultrafiltration Coefficient</title>
        <description>Ultrafiltration coefficient (Kuf) is the ratio of ultrafiltration rate in ml/hr to the Transmembrane pressure in mmHg. Both the Ultrafiltration rate and the transmembrane pressure readings are collected from the machine.</description>
        <time_frame>15 minutes after the recorded start of hemodialysis with Endexo upon its first use in the study</time_frame>
        <population>Subjects who are in the safety population, and have a minimum of 36 HD treatments with the dialyzer with Endexo.</population>
        <group_list>
          <group group_id="O1">
            <title>Endexo</title>
            <description>Hemodialysis treatments on the dialyzer with Endexo starts at visit 13 and continues until visit 50. Dialysis is performed 3 times per week which means the total of the intervention will be 13 weeks.&#xD;
Dialyzer with Endexo: Hemodialysis treatments on the dialyzer with Endexo starts at visit 13 and continues until visit 50. Dialysis is performed 3 times per week which means the total of the intervention will be 13 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance of the Dialyzer With Endexo by Measuring Its in Vivo Ultrafiltration Coefficient</title>
          <description>Ultrafiltration coefficient (Kuf) is the ratio of ultrafiltration rate in ml/hr to the Transmembrane pressure in mmHg. Both the Ultrafiltration rate and the transmembrane pressure readings are collected from the machine.</description>
          <population>Subjects who are in the safety population, and have a minimum of 36 HD treatments with the dialyzer with Endexo.</population>
          <units>mL/hr/mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.36" spread="9.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Any Adverse Events</title>
        <description>All adverse events were captured from subject enrollment to the completion of Optiflux period, and to the end of study or withdraws from the study.</description>
        <time_frame>Optiflux: from enrollment, weeks 1 to 4 (visits 1 to 12); Endexo: from weeks 5 to 17, and follow-up, a total of 17 weeks intervention.</time_frame>
        <population>Subjects who sign the ICF, are eligible, are enrolled in the study for Optiflux, and have at least one HD treatment with Endexo dialyzer for Endexo.</population>
        <group_list>
          <group group_id="O1">
            <title>Optiflux</title>
            <description>Optiflux dialyzer: Hemodialysis treatments on the optiflux dialyzer starts at visit 1 and continues until visit 12.</description>
          </group>
          <group group_id="O2">
            <title>Endexo</title>
            <description>Dialyzer with Endexo: Hemodialysis treatments on the dialyzer with Endexo starts at visit 13 and continues until visit 50.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Any Adverse Events</title>
          <description>All adverse events were captured from subject enrollment to the completion of Optiflux period, and to the end of study or withdraws from the study.</description>
          <population>Subjects who sign the ICF, are eligible, are enrolled in the study for Optiflux, and have at least one HD treatment with Endexo dialyzer for Endexo.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Any Device-related Adverse Events</title>
        <description>Any device-related adverse events were captured from subject enrollment to the completion of Optiflux period, and to the end of study or withdraws from the study.</description>
        <time_frame>Optiflux: from enrollment, weeks 1 to 4 (visits 1 to 12); Endexo: from weeks 5 to 17, and follow-up, a total of 17 weeks intervention.</time_frame>
        <population>Subjects who sign the ICF, are eligible, are enrolled in the study for Optiflux, and have at least one HD treatment with Endexo dialyzer for Endexo.</population>
        <group_list>
          <group group_id="O1">
            <title>Optiflux</title>
            <description>Optiflux d: Hemodialysis treatments on the dialyzer with Endexo starts at visit 1 and continues until visit 12.</description>
          </group>
          <group group_id="O2">
            <title>Endexo</title>
            <description>Dialyzer with Endexo: Hemodialysis treatments on the dialyzer with Endexo starts at visit 13 and continues until visit 50.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Any Device-related Adverse Events</title>
          <description>Any device-related adverse events were captured from subject enrollment to the completion of Optiflux period, and to the end of study or withdraws from the study.</description>
          <population>Subjects who sign the ICF, are eligible, are enrolled in the study for Optiflux, and have at least one HD treatment with Endexo dialyzer for Endexo.</population>
          <units>participants, events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Removal of Urea</title>
        <description>URR = (pre-HD urea - post-HD urea)/pre-HD urea * 100&#xD;
Data across visits were averaged for each subject, and then a group mean and sd were calculated.</description>
        <time_frame>At visits 1/week 1, 10/week 4, 13/week 5, 22/week 8, 34/week 12, and 46/week 16</time_frame>
        <population>Subjects who are in the safety population, and have a minimum of 36 HD treatments with the dialyzer with Endexo.</population>
        <group_list>
          <group group_id="O1">
            <title>Optiflux</title>
            <description>Optiflux dialyzer: Hemodialysis treatments on the dialyzer with Endexo starts at visit 1 and continues until visit 12.</description>
          </group>
          <group group_id="O2">
            <title>Endexo</title>
            <description>Dialyzer with Endexo: Hemodialysis treatments on the dialyzer with Endexo starts at visit 13 and continues until visit 50.</description>
          </group>
        </group_list>
        <measure>
          <title>Removal of Urea</title>
          <description>URR = (pre-HD urea - post-HD urea)/pre-HD urea * 100&#xD;
Data across visits were averaged for each subject, and then a group mean and sd were calculated.</description>
          <population>Subjects who are in the safety population, and have a minimum of 36 HD treatments with the dialyzer with Endexo.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.81" spread="4.33"/>
                    <measurement group_id="O2" value="81.87" spread="5.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Removal of Albumin</title>
        <description>%change = (post-HD - pre-HD)/pre-HD * 100</description>
        <time_frame>Pre- and Post- HD at Visits 1/week 1, 13/week 5</time_frame>
        <population>Subjects who are in the safety population, and have a minimum of 36 HD treatments with the dialyzer with Endexo.</population>
        <group_list>
          <group group_id="O1">
            <title>Optiflux</title>
            <description>Optiflux dialyzer: Hemodialysis treatments on the dialyzer with Endexo starts at visit 1 and continues until visit 12.</description>
          </group>
          <group group_id="O2">
            <title>Endexo</title>
            <description>Dialyzer with Endexo: Hemodialysis treatments on the dialyzer with Endexo starts at visit 13 and continues until visit 50.</description>
          </group>
        </group_list>
        <measure>
          <title>Removal of Albumin</title>
          <description>%change = (post-HD - pre-HD)/pre-HD * 100</description>
          <population>Subjects who are in the safety population, and have a minimum of 36 HD treatments with the dialyzer with Endexo.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.89" spread="8.63"/>
                    <measurement group_id="O2" value="7.99" spread="7.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Removal of Beta-2-microglobulin</title>
        <description>% reduction = (post-HD - pre-HD)/pre-HD * 100 with post-HD B2M adjusted to pre- and post HD weights</description>
        <time_frame>Pre- and Post- HD at Visits 1/week 1, 13/week 5</time_frame>
        <population>Subjects who are in the safety population, and have a minimum of 36 HD treatments with the dialyzer with Endexo.&#xD;
One subject in this pop did not have lab results for pre- and post beta-2-microglobulin in Endexo period. Therefore n=16 instead of 17.</population>
        <group_list>
          <group group_id="O1">
            <title>Optiflux</title>
            <description>Optiflux dialyzer: Hemodialysis treatments on the dialyzer with Endexo starts at visit 1 and continues until visit 12.</description>
          </group>
          <group group_id="O2">
            <title>Endexo</title>
            <description>Dialyzer with Endexo: Hemodialysis treatments on the dialyzer with Endexo starts at visit 13 and continues until visit 50.</description>
          </group>
        </group_list>
        <measure>
          <title>Removal of Beta-2-microglobulin</title>
          <description>% reduction = (post-HD - pre-HD)/pre-HD * 100 with post-HD B2M adjusted to pre- and post HD weights</description>
          <population>Subjects who are in the safety population, and have a minimum of 36 HD treatments with the dialyzer with Endexo.&#xD;
One subject in this pop did not have lab results for pre- and post beta-2-microglobulin in Endexo period. Therefore n=16 instead of 17.</population>
          <units>percent reduction, corrected</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.86" spread="7.16"/>
                    <measurement group_id="O2" value="67.73" spread="16.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Dialyzer Hemocompatibility</title>
        <description>The dialyzer hemo-compatibility is measured by measuring the activation of the complement system (C3a, C5a, SC5b-9)</description>
        <time_frame>Assessed at the first time the dialyzers are used in the study , collected pre hemodialysis and 30 minutes after the recorded start of hemodialysis</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Clotting of the Dialyzer</title>
        <description>Thrombus scoring will be assessed according to a clotting scale (The graded scoring method)</description>
        <time_frame>visual evaluation of the dialyzer arterial cap will be performed at the end of every hemodialysis treatment to determine the Grade:1,2,3 or 4. (1:no clotting to 4: total clotting), throughout a total of 17 weeks intervention.</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>a max of 22 weeks for a subject to complete the study</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Optiflux</title>
          <description>Hemodialysis treatments on Optiflux dialyzer starts at visit 1 and continues for 4 weeks to visit 12. Dialysis is performed 3 times per week which means the total of the intervention will be 13 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Endexo</title>
          <description>Hemodialysis treatments on the dialyzer with Endexo starts at visit 13 and continues until visit 50. Dialysis is performed 3 times per week which means the total of the intervention will be 13 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <description>GASTROINTESTINAL BLEEDING</description>
                <counts group_id="E1" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Localised infection</sub_title>
                <description>RIGHT FOOT INFECTION</description>
                <counts group_id="E1" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <description>HYPERTENSIVE EMERGENCY</description>
                <counts group_id="E1" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Orbital oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Bowel movement irregularity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Tissue infiltration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vascular access site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vascular access site thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Director of Statistics and Data Management</name_or_title>
      <organization>Fresenius Medical Care North America</organization>
      <phone>781-699-4203</phone>
      <email>ChiangHong.Ho@fmc-na.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

